 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that ARVN's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Arvinas (ARVN, $23.1) RSI Indicator left the oversold zone on September 21, 2023

Arvinas, Inc. (NASDAQ:ARVN  Get Free Report) has been assigned a consensus rating of Moderate Buy from the fifteen analysts that are presently covering the stock, MarketBeat...

Arvinas, Inc. (NASDAQ:ARVN) Receives $64.07 Consensus Target Price from Analysts

This price move could indicate a change in the trend, and may be a sell signal for investors...

Arvinas (ARVN, $24.4) price exceeded its 50-day Moving Average on September 15, 2023

This indicator may be signaling ARVN's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Arvinas (ARVN, $26.73) entered Uptrend as Momentum indicator ascends above 0 level on Sep 13, 2023

This indicator may be signaling that ARVN's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Arvinas (ARVN, $26.36) entered Downtrend as Momentum indicator drops below 0 level on Sep 12, 2023

This is a Bearish indicator signaling ARVN's price could decline from here. Traders may explore shorting the stock or put options...

Arvinas (ARVN, $26.36) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 12, 2023

This is a Bullish indicator signaling ARVN's price could rise from here. Traders may explore going long the stock or buying call options...

Arvinas (ARVN, $27.62) Moving Average Convergence Divergence (MACD) Histogram turned positive on September 8, 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Arvinas management 'excited to share' bavdegalutamide data, says Stifel

Arvinas (ARVN, $26.32) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 7, 2023

This is a signal that ARVN's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Arvinas (ARVN, $26.62) Stochastic Oscillator left the overbought zone on September 06, 2023

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Watchers	1,019
52-Wk Low	$21.21
52-Wk High	$57.96

Market Cap	$1.22B
Volume (M)	502,853.00
52-Wk High	$57.96
52-Wk Low	$21.21

ARVN Arvinas Inc

About

Feed

News

Sentiment

Earnings

Fundamentals